ProCE Banner Activity

CE / CME

Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Podcast Episodes

Listen in as Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the CLL guidelines from the NCCN and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes.

Physician Assistants: maximum of 1.00 hour of AAPA Category 1 CME credit

Registered Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: May 09, 2024

Expiration: May 08, 2025

Share

Faculty

Danielle M Brander

Danielle M Brander, MD

Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina

Brian Hill

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Deborah M Stephens

Deborah M Stephens, DO

Associate Professor
Director of the CLL and Richters Program
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hil
Chapel Hill, North Carolina

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeiGene and Lilly.

AstraZeneca

BeiGene

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner

Target Audience

This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with CLL/SLL.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Chronic Lymphocytic Leukemia (CLL).

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Select first-line therapy for treatment-naive CLL/SLL, taking into consideration the regimen’s toxicity profile, prognostic variables, comorbidities, duration, and patient preference

  • Plan an individual treatment approach including sequence of therapy for relapsed/refractory CLL/SLL to optimize clinical benefit and quality of life in alignment with patient preference

  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents with the similar molecular target

Disclosure

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers, and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions 

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Primary Author

Danielle M Brander, MD

Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina

Danielle M. Brander, MD: consultant/advisor: AbbVie, Genentech, Pharmacyclics; researcher (paid to institution): AbbVie, ArQule/Merck, Ascentage, AstraZeneca/Acerta, BeiGene, Catapult, DTRM, Genentech, Juno/Celgene/Bristol Myers Squibb, MEI Pharma, NeWave, Novartis, Pharmacyclis, TG Therapeutics.

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Brian Hill, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Kite, Novartis.

Deborah M Stephens, DO

Associate Professor
Director of the CLL and Richters Program
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hil
Chapel Hill, North Carolina

Deborah M. Stephens, DO: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Celgene, Genentech, Janssen, Lilly, Pharmacyclics; researcher: AbbVie, AstraZeneca, BeiGene, Genentech, Novartis.

None of the other planners/managers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients. 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 09, 2024, through May 08, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1 contact hour. 

Continuing Pharmacy Education

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-038-H01-P

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until May 08, 2025. PAs should only claim credit commensurate with the extent of their participation.